News & Media
Follow our news
Learn moreNews
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
2024-06-25
PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk
2024-06-24
Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes
2024-06-13
PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment
2024-05-14
PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered
2024-04-05
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treatedwith its Treg therapy in combination with rituximab
2024-03-11
PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.
2024-02-21
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
2024-02-07
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
2024-01-30
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
2024-01-16
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
